These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22783927)

  • 41. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhancing tumor penetration and targeting using size-minimized and zwitterionic nanomedicines.
    Zhang Y; Chen W; Yang C; Fan Q; Wu W; Jiang X
    J Control Release; 2016 Sep; 237():115-24. PubMed ID: 27397491
    [No Abstract]   [Full Text] [Related]  

  • 43. Peptide-Based Stealth Nanoparticles for Targeted and pH-Triggered Delivery.
    Ranalli A; Santi M; Capriotti L; Voliani V; Porciani D; Beltram F; Signore G
    Bioconjug Chem; 2017 Feb; 28(2):627-635. PubMed ID: 28107619
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model.
    Cabanes A; Tzemach D; Goren D; Horowitz AT; Gabizon A
    Clin Cancer Res; 1998 Feb; 4(2):499-505. PubMed ID: 9516942
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
    Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
    Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel long-circulating liposomes containing peptide library-lipid conjugates: synthesis and in vivo behavior.
    Riché EL; Erickson BW; Cho MJ
    J Drug Target; 2004 Jul; 12(6):355-61. PubMed ID: 15545085
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
    Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
    Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improved anti-breast cancer activity by doxorubicin-loaded super stealth liposomes.
    Paolino D; d'Avanzo N; Canato E; Ciriolo L; Grigoletto A; Cristiano MC; Mancuso A; Celia C; Pasut G; Fresta M
    Biomater Sci; 2024 Jul; 12(15):3933-3946. PubMed ID: 38940612
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
    Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
    Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
    Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
    Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel Galactosylated Poly(ethylene glycol)-Cholesterol for Liposomes as a Drug Carrier for Hepatocyte-Targeting.
    Zhang H; Xiao Y; Cui S; Zhou Y; Zeng K; Yan M; Zhao C
    J Nanosci Nanotechnol; 2015 Jun; 15(6):4058-69. PubMed ID: 26369013
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin.
    Tagami T; Ernsting MJ; Li SD
    J Control Release; 2011 Jun; 152(2):303-9. PubMed ID: 21338635
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
    Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H
    Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nuclear delivery of a therapeutic peptide by long circulating pH-sensitive liposomes: benefits over classical vesicles.
    Ducat E; Deprez J; Gillet A; Noël A; Evrard B; Peulen O; Piel G
    Int J Pharm; 2011 Nov; 420(2):319-32. PubMed ID: 21889584
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity.
    Metselaar JM; Bruin P; de Boer LW; de Vringer T; Snel C; Oussoren C; Wauben MH; Crommelin DJ; Storm G; Hennink WE
    Bioconjug Chem; 2003; 14(6):1156-64. PubMed ID: 14624629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel tumor-targeted thermosensitive liposomal cerasome used for thermally controlled drug release.
    Li S; Yin G; Pu X; Huang Z; Liao X; Chen X
    Int J Pharm; 2019 Oct; 570():118660. PubMed ID: 31491484
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
    Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y
    J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug.
    Ahmed F; Pakunlu RI; Brannan A; Bates F; Minko T; Discher DE
    J Control Release; 2006 Nov; 116(2):150-8. PubMed ID: 16942814
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oleanolic acid liposomes with polyethylene glycol modification: promising antitumor drug delivery.
    Gao D; Tang S; Tong Q
    Int J Nanomedicine; 2012; 7():3517-26. PubMed ID: 22848175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.